

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES, INC.

Petitioner,

v.

CELGENE CORP.

Patent Owner.

CASE NO. IPR2018-01507

Patent No. 8,404,717

**DECLARATION OF MARK LEVIN, M.D., IN SUPPORT OF
PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 8,404,717**

TABLE OF CONTENTS

	Page
I. QUALIFICATIONS AND BACKGROUND	5
A. Education and Experience.....	5
B. Materials Considered.....	9
C. Scope of Work.....	9
II. SUMMARY OF OPINIONS	10
III. LEGAL STANDARDS	12
IV. PERSON OF ORDINARY SKILL IN THE ART	15
V. BACKGROUND	16
A. MDS and Its Classification and Treatment.....	16
B. Thalidomide.....	27
C. Lenalidomide.....	29
VI. SCOPE AND CONTENT OF THE PRIOR ART REFERENCES	34
A. TNF α Was a Focus for MDS Treatment.....	36
1. Shetty 1996 [Ex. 1015].....	37
B. Thalidomide Clinical Trials in MDS Were Successful and Promising.....	38
1. Raza 2000b [Ex. 1021].....	38
2. Raza 2000d [Ex. 1022].....	39
3. Raza 2001 [Ex. 1023].....	41
4. Thomas 2000a [Ex. 1005].....	43
C. A POSA Had Knowledge of Revimid.....	46
1. Thomas 2000a [Ex. 1005].....	48
2. Corral 1999b [Ex. 1016].....	48
3. Marriott 2001 [Ex. 1017].....	51
4. Celgene Press Release 8/28/2001 [Ex. 1010].....	54
5. The '230 Patent [Ex. 1006].....	56

TABLE OF CONTENTS

(continued)

	Page
D. A POSA Had Knowledge of the Clinical Administration of Revimid	57
1. List 2001 [Ex. 1004]	57
2. Ritter 2001 [Ex. 1014]	59
3. Celgene Press Release 5/8/2001 [Ex. 1008]	59
4. Celgene Press Release 6/7/2001 [Ex. 1009]	63
VII. THE CONTESTED CLAIMS OF THE '717 PATENT ARE UNPATENTABLE	64
A. Ground 1: Claims 1–10 were unpatentable as obvious over List 2001 in view of the '230 patent and the Celgene Press Releases 5/8/2001 and 8/28/2001	65
1. Claim 1 was unpatentable as obvious over List 2001 in view of the '230 patent and Celgene Press Releases 5/8/2001 and 8/28/2001	67
a. Use of Revimid to treat MDS-caused TDA	67
b. Revimid's chemical name and structure.....	72
c. Administration of about 5–25 mg/day Revimid to Treat MDS-caused TDA.....	74
2. Dependent claim 10 was obvious	82
3. Dependent claims 2, 4, 6, and 8 were obvious	83
4. Dependent claims 3, 5, 7, and 9 were obvious	84
B. Ground 2: Claims 1–10 were unpatentable as obvious over Thomas 2000a in view of the '230 patent and the Celgene Press Releases 5/8/2001 and 8/28/2001.....	86
1. Claim 1 was unpatentable as obvious over Thomas 2000a in view of the 230 patent and Celgene Press Releases 5/8/2001 and 8/28/2001	88
a. Use of lenalidomide (and thalidomide) to treat MDS-caused TDA	88
b. Revimid structure	93

TABLE OF CONTENTS

(continued)

Page

c. Administration of about 5–25 mg/day Revimid to treat MDS-caused TDA	94
2. Dependent claim 10 was obvious	97
3. Dependent claims 2, 4, 6, and 8 were obvious	98
4. Dependent claims 3, 5, 7, and 9 were obvious	98
VIII. CONCLUSION	100

I. QUALIFICATIONS AND BACKGROUND

A. Education and Experience

1. My name is Mark Levin. I am a medical oncologist with 28 years of experience treating patients with myelodysplastic syndrome and multiple myeloma. Throughout my career, I have engaged in clinical research, including writing and conducting clinical trials, writing papers, and performing clinical as well as administrative work related to cancer medicine in a variety of settings. My full curriculum vitae (CV) is attached hereto as Exhibit A and is incorporated herein.

2. I received a Bachelor's degree in Pre-Medical Studies from Yeshiva University in 1980. I received my M.D. from State University of New York (SUNY) in Brooklyn in 1984. I later completed an M.B.A. program from the Herriott-Watt University, Edinburgh Business School, in 2005.

3. After graduating from medical school, I completed my internship at Hahnemann University Medical Center (now Drexel University College of Medicine) in 1985–1986 and my residency in Internal Medicine at New York Downtown Hospital in New York City from 1986–1987. Afterward, from 1987–1990, I completed a three-year program in Hematology and Oncology at the Long Island Jewish Hillside Hospital Medical Center, in New Hyde Park, New York.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.